Highest-materiality recent filing
Business Combination Agreement with GH Power: MTNB shareholders receive 0.1 Pubco share per MTNB share; GH Power holders get ~91% of combined entity.
Matinas BioPharma receives NYSE American non-compliance notice; granted plan period through Oct 2027
Stockholders' equity of $3.02M as of March 31, 2026 fails the $4M minimum under Section 1003(a)(ii) of NYSE American Guide.
Matinas BioPharma receives NYSE American delisting notice for low equity
Stockholders' equity was $4.83M as of Dec 31, 2025, below the $6M threshold for five years of losses.
Matinas BioPharma CFO Keith Kucinski resigns; CEO Jerome Jabbour named interim CFO
Keith Kucinski resigned as CFO effective January 17, 2026, to pursue other opportunities.
Retention bonus trigger extended from Mar 31, 2026 to Jun 30, 2026; 2/3 paid upon signing definitive agreement, 1/3 at closing.
Matinas BioPharma CFO Keith Kucinski to resign effective Jan 17, 2026
Keith Kucinski notified his resignation as CFO on Nov 18, 2025.
Matinas BioPharma exchanges 466,666 warrants for common stock; cancels $17.50 strike warrants
Entered into Warrant Exchange Agreements on Aug 15, 2025 with certain warrant holders.
Matinas BioPharma increases authorized common stock to 500M shares
Authorized common shares doubled from 250M to 500M effective Aug 6, 2025.
Stockholders approve reverse split up to 1:199, authorized shares to 500M, and new equity plan
All five director nominees elected; advisory vote on executive compensation passes with 5.56M for, 0.11M against.
Board reduced stockholder quorum from majority to one-third of voting power to facilitate meetings.
Matinas BioPharma closes $1.65M second tranche of Series C preferred & warrant offering
Second closing on April 8, 2025 raised $1.65M from sale of 1,650 Series C Convertible Preferred shares.
Matinas BioPharma shareholders approve issuance of up to 16.9M shares and ratify auditor
Proposal 1 passed with 88% of votes cast; authorizes up to 16,894,212 common shares upon conversion of Series C Preferred and warrants.
Matinas BioPharma Chairman Eric Ende resigns from Board effective March 14
Eric Ende resigned as Board member and Chairman on March 14, 2025.
Matinas BioPharma appoints Keith Murphy and Edward Neugeboren to board; two directors resign
Natasha Giordano and Matthew Wikler resigned from the Board effective Feb 11, 2025, not due to any disagreement.
Matinas raises $3.3M via Series C preferred and warrants; appoints Dr. Robin Smith to board
Initial closing of $1.65M for 1,650 Series C shares; second $1.65M closing subject to shareholder approval by April 10, 2025.
Matinas BioPharma director Herbert Conrad resigns due to retirement
Herbert Conrad resigned from Board of Directors effective February 6, 2025.
Matinas BioPharma appoints Evelyn D'An as independent director and Audit Committee Chair
Evelyn D'An appointed to board effective February 5, 2025 as independent director and Audit Committee Chair.
Matinas BioPharma director James Scibetta resigns from board effective Jan 21, 2025
James S. Scibetta resigned from the Board of Directors effective January 21, 2025.
Matinas BioPharma receives NYSE American notice for failure to hold 2024 annual meeting
On January 6, 2025, Matinas received NYSE American notice for failing to hold 2024 annual meeting, violating Section 704.
Director Kathryn Penkus Corzo resigns from Matinas BioPharma board effective Nov 22, 2024
Director Kathryn Penkus Corzo resigned from Board effective Nov 22, 2024, citing other professional obligations.
Partnership negotiations for MAT2203 global rights terminated; prospective partner withdrew.
Matinas BioPharma CDO resigns; CMO and VP Clinical Dev to assume duties
Chief Development Officer Theresa Matkovits resigned effective October 23, 2024, to pursue another opportunity.
Effective Aug 30, 2024, Matinas executed a 1:50 reverse stock split and reduced authorized shares from 500M to 250M.
Matinas BioPharma receives NYSE American trading halt due to low price; plans 1-for-50 reverse split
Trading of MTNB common stock halted by NYSE American on August 27, 2024 due to low trading price.
Matinas BioPharma announces 1-for-50 reverse stock split effective Aug 30, 2024
Board approved 1-for-50 reverse stock split and reduction of authorized shares from 500M to 250M.
Matinas BioPharma Q2 net loss $5.7M ($0.02/sh); signs non-binding MAT2203 term sheet
Net loss for Q2 2024 was $5.7 million ($0.02 per share), compared to $6.1 million ($0.03) in Q2 2023.
Matinas BioPharma Q1 2024 net loss $5.8M; raises $10M in April, expects cash into Q2 2025
Q1 2024 revenue $0 vs $1.1M in Q1 2023; net loss $5.8M ($0.03 per share).
Matinas BioPharma raises $10M in registered direct offering of common stock and warrants
Sold 33,333,334 shares and warrants at $0.30/unit; gross proceeds ~$10M.
Matinas BioPharma updates corporate presentation; no material new information disclosed
Furnished updated corporate presentation dated March 28, 2024 under Regulation FD.
Matinas BioPharma reports 2023 net loss $22.9M; cash runway only through Q3 2024
Revenue fell to $1.1M from $3.2M; net loss per share $0.11 vs $0.10 prior year.
Total docetaxel delivered orally via LNC was >8x IV dose by Day 22; all IV mice lost avg 20% weight, LNC mice maintained weight normal.
Matinas BioPharma regains NYSE American continued listing compliance
Received notification on March 21, 2024, resolving low selling price deficiency under Section 1003(f)(v).
Matinas BioPharma reports complete clinical response in 3 fusarium patients with oral MAT2203
Three patients with azole-resistant invasive fusarium infection achieved complete clinical response after oral MAT2203 treatment.
19 patients enrolled in compassionate-use program for oral antifungal MAT2203; 15 evaluable.
FDA agrees on Phase 3 trial design for Matinas' MAT2203 in invasive aspergillosis
FDA agreed on design of single Phase 3 ORALTO trial for MAT2203 in invasive aspergillosis; primary endpoint all-cause mortality at day 42.
Matinas BioPharma updates corporate presentation; no specific disclosures
Filed an updated corporate presentation dated January 9, 2024, for use at conferences and investor meetings.
Orally LNC-formulated small oligonucleotide targeting TNFα reduced serum TNFα by 37% in DSS-induced colitis model.
FDA provided written comments on revised Phase 3 protocol for MAT2203 in invasive aspergillosis with limited treatment options.
Matinas BioPharma updates corporate presentation; no specifics available
Corporate presentation updated as of November 20, 2023.
Matinas BioPharma oral LNC docetaxel shows tumor reduction comparable to IV in melanoma model
Oral LNC docetaxel reduced tumor volume 63% (high dose) and 57% (low dose) vs 68% for IV docetaxel at Day 14.
Matinas BioPharma reports Q3 net loss $6.1M; FDA supports MAT2203 Phase 3 with LPAD pathway
Net loss of $6.1M ($0.03 per share) in Q3 2023 vs $5.5M in Q3 2022; no revenue vs $1.1M from BioNTech in prior year.
Matinas BioPharma shareholders approve reverse stock split and reelect directors
All 7 director nominees elected; Eric Ende received 57.9M for, 10.1M withheld; 59.1M broker non-votes.
Matinas BioPharma receives NYSE American deficiency notice for low price; must cure by Mar 2024
Received NYSE American deficiency letter for non-compliance with Section 1003(f)(v) due to 30-day avg closing price below $0.20.
Matinas BioPharma updates corporate presentation for investor meetings
Corporate presentation updated as of September 20, 2023 for use at conferences.
Matinas BioPharma Q2 net loss $6.1M; FDA sets 700-patient bar for MAT2203 first-line
Q2 2023 revenue $0 (vs $1.1M in Q2 2022); net loss $6.1M ($0.03/sh) vs $5.9M.
Matinas BioPharma concludes BioNTech mRNA collaboration, plans Phase 3 trial for MAT2203 antifungal
BioNTech oral mRNA collaboration ended; in vivo oral study showed no activity, but systemic delivery and stability demonstrated.
Patient treated with MAT2203 achieved complete clinical resolution of R. mucilaginosa infection after 6 months and regained use of foot.
Matinas BioPharma reports 2022 net loss $21M, cash $28.8M; LNC platform updates
Revenue $3.2M from BioNTech collaboration, vs $33K in 2021.
Preliminary cash of $28.8M at Dec 31, 2022, down from $49.6M at Dec 31, 2021; runway projected into Q2 2024.
Matinas BioPharma partners with Resilience to explore oral nucleic acid delivery via LNC platform
Material Transfer and Evaluation Agreement with National Resilience for oral delivery of nucleic acids.
On March 13, 2025, Eric Ende informed the Board of Directors (the “ Board ”) of Matinas BioPharma Holdings, Inc. (the “ Company ”) that he was resigning as a member of the Board and as Chairman of the Board effective March 14, 2025, due to his other professional obligations.
The Board appointed Mr. Neugeboren to serve as a member of the Audit Committee and as Chair of the Compensation Committee.
On February 10, 2025, Natasha Giordano informed the Board of Directors (the “ Board ”) of Matinas BioPharma Holdings, Inc. (the “ Company ”) that she was resigning from the Board effective February 11, 2025, due to her other professional obligations.
On February 10, 2025, Matthew Wikler informed the Board that he was resigning from the Board effective February 11, 2025, due to his other professional obligations.
Effective as of March 11, 2025, the Board, on the recommendation of the Governance Committee, appointed Keith Murphy and Edward Neugeboren directors of the Company to replace Ms. Giordano and Mr. Wikler, respectively.
the Board, on the recommendation of its Nominating and Corporate Governance Committee, appointed Robin Smith director of the Company.
On February 5, 2025, Herbert Conrad informed the Board of Directors (the “ Board ”) of Matinas BioPharma Holdings, Inc. (the “ Company ”) that he was resigning from the Board effective February 6, 2025, due to retirement.
the employment of James Ferguson, M.D., the Company’s Chief Medical Officer, was terminated effective October 31, 2024.
On December 6, 2021, Matinas BioPharma Holdings, Inc. (the “Company” or “Matinas”) announced that Thomas Hoover, age 52, has been appointed as the Company’s Chief Business Officer.
On September 17, 2021, director Patrick LePore informed the Board of Directors (the “Board”) of Matinas BioPharma Holdings, Inc. (the “Company”) that he will not stand for re-election to the Board at the upcoming annual meeting of stockholders, which will be held on November 1, 2021 (the “Annual Meeting”).
Max materiality 1.00 · Median 0.65 · Most common event other_material